Loading
Life sciences · Journal article
Frontiers in Pharmacology · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Mitochondrial dysfunction is a convergent pathological feature of neurodegenerative, metabolic, cardiovascular, hepatic, and cancer-related disorders, making mitochondrial homeostasis an important therapeutic target. Natural polysaccharides (NPs) are structurally diverse macromolecules that have emerged as promising multifunctional modulators of mitochondrial homeostasis. This review summarizes the structural basis and mechanistic actions underlying the mitochondrial regulatory effects of NPs. Key structural features, including molecular weight, monosaccharide composition, glycosidic linkages, branching patterns, and chemical modifications, largely determine the mitochondria-regulating potential of NPs. Mechanistically, NPs regulate mitochondrial homeostasis by restoring bioenergetic function, reducing oxidative stress, maintaining mitochondrial quality control, and modulating mitochondria-dependent apoptosis. These effects support disease-context-specific therapeutic benefits, as NPs generally preserve mitochondrial homeostasis in non-malignant diseases while potentially inducing mitochondrial stress and cell death in cancer. This review also highlights key translational barriers to NP-based mitochondrial therapy, underscoring the need for standardized structural characterization, mechanism-oriented mitochondrial assays, and disease-specific evaluation.